Cardiac Amyloidosis Screening and Management in Patients with Heart Failure: An International African Survey
Starting on:
Nov 12, 2025
Ending on:
Feb 1, 2026
Moderator(s):
Mr. John Dawod
Public Health Researcher and Clinical Operations Leader; Founder and Chairman of CRK Clinical Research Key (CRK NGO) and CliniQuest Research Site, Nairobi. Principal Investigator for Kenya’s national cardiac amyloidosis awareness and diagnosis program in collaboration with the Kenya Cardiac Society and Mayo Clinic. Holds an MSc in International Public Health (Liverpool John Moores University, UK). Experienced in digital health, pharmacovigilance, and CPD-accredited e-learning development, leading nationwide education initiatives through CRKCourses.com.
URL:
Go to activity

Max Credits:
2 Points

Provider:
CRK CLINICAL RESEARCH KEY (CRO) LIMITED
Claim Points

Cardiac Amyloidosis Screening and Management in Patients with Heart Failure: An International African Survey

Starting on:
Nov 12, 2025
Ending on:
Feb 1, 2026
Venue:

Description

This online survey, conducted through Google Forms under the Kenya Cardiac Society (KCS)–CRK Clinical Research Key (NGO) collaboration, aims to assess awareness, diagnostic capacity, and management practices for cardiac amyloidosis (CA) among healthcare providers across Africa. The activity is part of the KCS Registry Program on Cardiac Amyloidosis Screening and Implementation Science in Kenya, supporting future AI-driven projects. Participants will provide insights on diagnostic tools (e.g., echocardiography, cardiac MRI, 99mTc-PYP scans, and genetic testing), access to disease-modifying therapies, and referral systems. The survey takes approximately 10–12 minutes to complete, and is fully voluntary and anonymous. Access the survey here: https://docs.google.com/forms/d/e/1FAIpQLScFpOrdu7ICeiOtS5lD7Op72aUWWlLBqwL8-tKJNBRSxHbB-A/viewform?usp=dialog

Objectives

Assess healthcare professionals’ awareness and experience in diagnosing and managing cardiac amyloidosis (CA). Evaluate availability and use of diagnostic tools such as echocardiography, cardiac MRI, 99mTc-PYP scintigraphy, and genetic testing. Identify barriers to accessing disease-modifying therapies and referral pathways. Generate baseline data to guide national and regional policy, training, and implementation science initiatives. Inform upcoming studies such as PREDICT-AMY Kenya on AI-powered ECG screening for cardiac amyloidosis in low-resource settings.

Presenters

Search For CPD Activity